IRIS
DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9
Totale 9
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 9
Totale 9
Salva come PNG Salva come JPEG
Città #
San Pietro Vernotico 9
Totale 9
Salva come PNG Salva come JPEG
Nome #
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial 5
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 4
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma 4
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial 3
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial 3
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer 3
Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer 3
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial 3
High-dose chemotherapy for adult-type ovarian granulosa cell tumors: a retrospective study of the European Society for Blood and Marrow Transplantation 1
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 1
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 1
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 1
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials 1
Consider quality of life to improve quality of cancer guidelines 1
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer 1
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 1
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 1
Methylation pattern analysis in prostate cancer tissue: Identification of biomarkers using an MS-MLPA approach 1
Immunotherapy for prostate cancer: Where we are headed 1
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 1
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 1
Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experience 1
Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? 1
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 1
Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. 1
Circulating tumor cells in newly diagnosed inflammatory breast cancer 1
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 1
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors 1
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 1
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 1
Ovarian Sertoli-Leydig cell tumor, endometrioid-like yolk sac tumor, and Y-chromosomal material 1
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger 1
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 1
Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments 1
Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey 1
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma 1
Circulating tumor cells in metastatic inflammatory breast cancer 1
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer 1
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT) 1
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial 1
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators 1
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study 1
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 1
Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies 1
[18F]fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy. 1
A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study 1
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study 1
Prevention and therapy of neutropenia in elderly patients 1
Erratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide [Eur J Nucl Med Mol Imaging, DOI 10.1007/s00259-015-3042-5] 1
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer 1
Psychosocial issues in long-term survivors of testicular cancer 1
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 1
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 1
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone 1
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study 1
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 1
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 1
Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer 1
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial 1
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide 1
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. 1
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 1
Early use of abiraterone and radium-223 in metastatic prostate cancer 1
Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features 1
Adjuvant concomitant chemotherapy in pancreatic cancer. 1
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer 1
Germ cell tumours of the testis 1
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial 1
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 1
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 1
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer 1
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 1
Anticancer drug delivery with nanoparticles 1
The prognostic value of pain in castration-sensitive prostate cancer 1
Cell-free DNA as a diagnostic marker for cancer: current insights 1
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors 1
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort 1
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 1
Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1 1
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study 1
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer 1
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer 1
Systemic immune-inflammation index in germ-cell tumours 1
The potential use of urine cell free DNA as a marker for cancer 1
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study 1
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 1
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis 1
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 1
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide 1
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 1
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society 1
Lhermitte's sign following oxaliplatin-containing chemotherapy in a cisplatin-pretreated ovarian cancer patient 1
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging 1
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 1
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 1
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 1
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. 1
High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry 1
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer 1
Dose intensification in hormone receptor–negative and/or human epidermal growth factor receptor 2–negative high-risk primary breast cancer. 1
Totale 120
Salva come PNG Salva come JPEG
Categoria #
all - tutte 614
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 614
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025306 0 0 0 0 0 0 306 0 0 0 0 0
Totale 306